|
NUP107 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.16319995249847E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.95509999967314E-07 |
| Normal-vs-Stage2 |
5.11370000011446E-07 |
| Normal-vs-Stage3 |
7.96769999977798E-08 |
| Normal-vs-Stage4 |
2.38700004207004E-09 |
| Stage1-vs-Stage2 |
2.065000E-01 |
| Stage1-vs-Stage3 |
4.044000E-01 |
| Stage1-vs-Stage4 |
7.565600E-02 |
| Stage2-vs-Stage3 |
5.445800E-01 |
| Stage2-vs-Stage4 |
9.945600E-01 |
| Stage3-vs-Stage4 |
4.394600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.59440000383427E-08 |
| Normal-vs-AfricanAmerican |
1.978410E-03 |
| Normal-vs-Asian |
2.181400E-04 |
| Caucasian-vs-AfricanAmerican |
6.841200E-01 |
| Caucasian-vs-Asian |
6.243800E-01 |
| AfricanAmerican-vs-Asian |
9.727800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.73129999225807E-09 |
| Normal-vs-Female |
2.53009999617859E-08 |
| Male-vs-Female |
4.320000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.04820000018857E-07 |
| Normal-vs-Age(41-60Yrs) |
1.75080000053285E-07 |
| Normal-vs-Age(61-80Yrs) |
5.34340016677959E-10 |
| Normal-vs-Age(81-100Yrs) |
2.435800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.021400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.563700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.846000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.479600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.016200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.909200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.343000E-01 |
| Classical-VS-Follicular |
2.6708000000486E-06 |
| Classical-VS-Other |
1.130350E-01 |
| Classical-VS-Normal |
6.57109999968597E-07 |
| Tall-VS-Follicular |
1.607650E-02 |
| Tall-VS-Other |
3.511600E-01 |
| Tall-VS-Normal |
2.808400E-04 |
| Follicular-VS-Other |
7.181600E-01 |
| Follicular-VS-Normal |
3.85550036341442E-10 |
| Other-VS-Normal |
3.138800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.62100016637612E-10 |
| Normal-vs-N1 |
1.26019999990845E-07 |
| N0-vs-N1 |
8.300800E-01 |
|
|
